Update your location to show providers, locations, and services closest to you.
Hello! My name is Dr. Haller but my patients call me Dr. Mike. I work as a Professor and Chief of Pediatric Endocrinology at the University of Florida. As a Gainesville native, and the child of two teachers, I was exposed from an early age to the many incredible educational opportunities afforded by our diverse and highly educated city. My early interests in biology and chemistry combined with my desire to help people and work with children led me pretty directly towards pursuing a career in pediatrics. My interest in pediatric endocrinology was shaped by my grandfather’s experience living with diabetes, experiences volunteering at the Florida Diabetes Camps, and exceptional mentoring from Drs. Desmond Schatz, Janet Silverstein and Mark Atkinson.
I have been involved in type 1 diabetes research since the early 1990s and have published over 200 manuscripts and more than 20 reviews/book chapters on type 1 diabetes pathogenesis, prevention, and interdiction. I am the principal investigator or co-investigator on numerous JDRF, NIH, and Helmsley trust funded studies. My goal is to work every day to improve the lives of children and families affected by type 1 diabetes. I am hopeful that during my career we will develop therapies that can meaningfully prevent and reverse type 1 diabetes.
In my free time, I enjoy spending time with my wife, Dr. Allison Haller (an Anesthesiologist and also a Gator Med School Grad), our 2 children, and our dogs. I also love to spend time in nature, watch live music, attend Gator sporting events, and fly planes.
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis.
The study is a two-arm, multicenter, double-blinded clinical trial testing sequential therapy with rituximab-pvvr followed by abatacept versus rituximab-pvvr alone in new onset T1D. The primary objective is to test whether the C-peptide response to…
A multi-center, placebo-controlled, double blind, 2:1 randomized control clinical trial testing low-dose ATG vs. placebo in subjects with a 2 year 50% risk of progression to stage 3 T1D.
Please note: Some physicians and practices might not accept a specific insurance plan. Our list is also subject to change, and sometimes that change is not yet reflected in this list. Please contact the practice to confirm that your insurance is accepted. A representative will be happy to assist you.
June 14, 2022
Related video: UF Health Shands Children’s Hospital ranked No. 1 in Florida University of Florida Health Shands Children’s Hospital continued its remarkable…
College of Medicine, UF Health Shands Children's Hospital, +2 more
September 4, 2020
For children with diabetes or other endocrine system disorders who come from less affluent families, access to care can be difficult and time-consuming.…
Department of Pediatrics, +2 more
